Marie-Odile ROY

En résumé

Entreprises

• Institut des Biothérapies - Association Française contre les Myopathies - Director of Pre-clinical Research & Development

  2012 - maintenant • Set up and manage Pre-clinical R&D Department
  • Supervise development of innovative therapies for the treatment of rare diseases including Advanced Therapy Medicinal Products (ATMP) such as cell- and gene-based products.
  • Provide expertise in non-clinical development strategy
  • Participate in projects evaluation & pipeline prioritization process
  • Work in close collaboration with Clinical and Regulatory Affairs Department

• Association Française contre les Myopathies - Senior R&D Manager - Scientific Direction

  TREMBLAY EN FRANCE cedex 2011 - maintenant • Supervise team of Project Managers
  • Coordinate pipeline of national and international translational pre-clinical and clinical R&D programs for the development of innovative therapeutics in the field of rare diseases & neuromuscular diseases: gene & cell therapy products, gene surgery tools (nucleases, antisense oligonucleotides, siRNA, …), small molecules (NCE) and repurposed drugs
  • Coordinate working groups of researchers, clinicians & patient representatives
  • Present AFM activities & missions to partners, donators and to the general public

• EUROSCREEN SA , Belgium - Project Manager

  2006 - 2011 o Managed several pluridisciplinary programs in various indications (CNS, immunoinflammation, hormone-related disorders, …) for the identification of pre-clinical, & clinical development candidates
  o Coordinate chemistry, ADME/PK-Tox and in vitro/in vivo pharmacology teams for identification and optimization of lead candidate (one orally-active candidate drug currently in phase I).
  o Present grant applications for National and EU research fundings

• EUROSCREEN SA, Belgium - Head of Compound Profiling (DMPK)

  2006 - 2011 Lead the DMPK (Drug Metabolism and Pharmacokinetics) team
  Supervise early ADME-Tox & PK studies
  
  • Managed a multidisciplinary team of 10 people
  • Created and lead the Compound Profiling (DMPK/Tox department, including in vitro group, in vivo group and analytical group)
  • Supervised internal & outsourced in vitro/in vivo ADME-Tox/Safety & PK studies to support hit-to-lead and lead optimization processes in early Discovery and Development of NCE
  • Support Chemistry team for compound formulation
  

• EUROSCREEN SA, Belgium - Head of Target Discovery/Target Validation

  2004 - 2006 • Manage Target Discovery & Target Validation team for identification of new G-Protein Coupled Receptors (GPCR) drug targets (GPCR deorphanization) for various indications
  • Supervise HTS campaigns for GPCR’s ligand identification
  • Master modern cellular pharmacology and ligand technologies, designed to assist in the structural and pharmacological characterization of GPCR/ligand interactions.

• AstraZeneca R&D, Montreal, Canada - Senior Scientist

  2000 - 2003 Search for new G-Protein Coupled Receptors (GPCRs) ligand (‘deorphanization’)
  • In charge of HTS campaigns to identify new GPCR ligand
  • Conduct pharmacological characterization of new GPCR/ligand couples

• AURELIUM BIOPHARMA, Montreal, Canada - Senior Scientist - Pharmacology

  2000 - 2000 • In charge of the Pharmacology team
  • Search for new targets in drug resistant cancers

Formations

• McGill University (Canada)

  Montréal 1997 - 2000 Postodctorate Fellow

• Faculté De Pharmacie (Montpellier)

  Montpellier 1994 - 1997 Doctorat

Réseau

• Delphine CARAYON

• Dominique CARAYON

• Hervé CHEBROU

• Marine CHAUVELOT

• Odile CAPRONNIER

• Typhaine MAROIS